Not a bad result given the climate!
Half year highlights
• Net profit up 31% to $7.2 million
• LANI completes Phase II and commences pivotal Phase III for Japan
• RSV licence with AstraZeneca extended into additional Asian & Pacific territories
for US$3.5 million
• Strong cash position maintained: $55.4 million at 31 December 2008
• Litigation against GSK concluded at mediation
Bodes well for BTA and on the watchlist
iPod
NEWSMAN
